Pharsight

Drugs that contain Drospirenone

1. Drospirenone patents expiration

DROSPIRENONE's oppositions filed in EPO
Can you believe DROSPIRENONE received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603281 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

US10849857 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

US9603860 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

US10179140 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

US11413249 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US10987364 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11351122 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11291632 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11291633 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11123299 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11439598 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11478487 EXELTIS USA INC NA
Jun, 2031

(7 years from now)

US11504334 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Jun 29, 2025

Market Authorisation Date: 29 June, 2022

Treatment: Prevention of pregnancy in females of reproductive age

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage

DROSPIRENONE family patents

Family Patents

2. Slynd patents expiration

SLYND's oppositions filed in EPO
Can you believe SLYND received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10179140 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

US9603860 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

US10603281 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

US10849857 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

US10987364 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11123299 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11478487 EXELTIS USA INC NA
Jun, 2031

(7 years from now)

US11413249 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11291633 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11351122 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11291632 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11439598 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11504334 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) May 23, 2022

Market Authorisation Date: 23 May, 2019

Treatment: Prevention of pregnancy in females of reproductive age

Dosage: TABLET;ORAL

How can I launch a generic of SLYND before it's drug patent expiration?
More Information on Dosage

SLYND family patents

Family Patents